JP2005514378A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514378A5 JP2005514378A5 JP2003548774A JP2003548774A JP2005514378A5 JP 2005514378 A5 JP2005514378 A5 JP 2005514378A5 JP 2003548774 A JP2003548774 A JP 2003548774A JP 2003548774 A JP2003548774 A JP 2003548774A JP 2005514378 A5 JP2005514378 A5 JP 2005514378A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- alkyloxy
- hydroxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 198
- -1 chloro, fluoro, phenyl Chemical group 0.000 claims 69
- 125000003545 alkoxy group Chemical group 0.000 claims 62
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 58
- 125000000753 cycloalkyl group Chemical group 0.000 claims 45
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 38
- 229910052736 halogen Chemical group 0.000 claims 30
- 150000002367 halogens Chemical group 0.000 claims 29
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 28
- 125000001544 thienyl group Chemical group 0.000 claims 28
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 239000002253 acid Substances 0.000 claims 26
- 125000002541 furyl group Chemical group 0.000 claims 26
- 125000003342 alkenyl group Chemical group 0.000 claims 22
- 229910052757 nitrogen Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 125000005297 thienyloxy group Chemical group S1C(=CC=C1)O* 0.000 claims 21
- 150000004702 methyl esters Chemical class 0.000 claims 17
- 125000004953 trihalomethyl group Chemical group 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 15
- 125000004414 alkyl thio group Chemical group 0.000 claims 14
- 125000000304 alkynyl group Chemical group 0.000 claims 13
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 12
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000001624 naphthyl group Chemical group 0.000 claims 8
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 125000005108 alkenylthio group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 125000001589 carboacyl group Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 239000011593 sulfur Chemical group 0.000 claims 5
- 125000003302 alkenyloxy group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 210000001525 retina Anatomy 0.000 claims 4
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 4
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- SCHJXJCLCWNPBA-UHFFFAOYSA-N 1-[6-(2H-tetrazol-5-yl)hexyl]pyrrolidin-2-one Chemical compound O=C1CCCN1CCCCCCC1=NNN=N1 SCHJXJCLCWNPBA-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 claims 2
- 108091005479 5-HT2 receptors Proteins 0.000 claims 2
- RSHHWIMRRJFJJN-GJOXONGWSA-N 7-[(2r)-2-[(e)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C1CCCCC1C(O)\C=C\[C@H]1CCC(=O)N1CCCCCCC(O)=O RSHHWIMRRJFJJN-GJOXONGWSA-N 0.000 claims 2
- DVDIXSPSNQPVNX-QHYGYJHXSA-N 7-[(2r)-2-[(e)-3-hydroxy-3-(1-phenylcyclopropyl)prop-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C1CC1(C=1C=CC=CC=1)C(O)\C=C\[C@H]1CCC(=O)N1CCCCCCC(O)=O DVDIXSPSNQPVNX-QHYGYJHXSA-N 0.000 claims 2
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000001344 Macular Edema Diseases 0.000 claims 2
- 206010025415 Macular oedema Diseases 0.000 claims 2
- 206010030043 Ocular hypertension Diseases 0.000 claims 2
- 125000005236 alkanoylamino group Chemical group 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000005422 alkyl sulfonamido group Chemical group 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 230000004410 intraocular pressure Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000010230 macular retinal edema Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 230000000324 neuroprotective effect Effects 0.000 claims 2
- 210000003733 optic disk Anatomy 0.000 claims 2
- 210000001328 optic nerve Anatomy 0.000 claims 2
- 239000000734 parasympathomimetic agent Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 2
- 229940127230 sympathomimetic drug Drugs 0.000 claims 2
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- GGUSQTSTQSHJAH-FQEVSTJZSA-N (R)-eliprodil Chemical compound C([C@H](O)C=1C=CC(Cl)=CC=1)N(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-FQEVSTJZSA-N 0.000 claims 1
- NWIUTZDMDHAVTP-KRWDZBQOSA-N (S)-betaxolol Chemical compound C1=CC(OC[C@@H](O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-KRWDZBQOSA-N 0.000 claims 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical group O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical group C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 claims 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- IGVPZJXNGDQLRO-MUEFQPRUSA-N 7-[(2r)-2-[(e)-3-hydroxy-3-methyl-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C(\[C@@H]1N(C(=O)CC1)CCCCCCC(O)=O)=C/C(O)(C)CC1=CC=CC=C1 IGVPZJXNGDQLRO-MUEFQPRUSA-N 0.000 claims 1
- QJAUBUSJQRXFTG-GETIXZKPSA-N 7-[(2r)-2-[(e)-3-hydroxy-4-methyl-4-phenylpent-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid Chemical compound C=1C=CC=CC=1C(C)(C)C(O)\C=C\[C@H]1CCC(=O)N1CCCCCCC(O)=O QJAUBUSJQRXFTG-GETIXZKPSA-N 0.000 claims 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 229920002148 Gellan gum Polymers 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 229960000571 acetazolamide Drugs 0.000 claims 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 claims 1
- 229960004324 betaxolol Drugs 0.000 claims 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims 1
- 229960003679 brimonidine Drugs 0.000 claims 1
- 229960000722 brinzolamide Drugs 0.000 claims 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 claims 1
- 229960001222 carteolol Drugs 0.000 claims 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002896 clonidine Drugs 0.000 claims 1
- 229960003933 dorzolamide Drugs 0.000 claims 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical group CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229950005455 eliprodil Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 235000010492 gellan gum Nutrition 0.000 claims 1
- 239000000216 gellan gum Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 229940095437 iopidine Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 1
- 229960001160 latanoprost Drugs 0.000 claims 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims 1
- 229960004771 levobetaxolol Drugs 0.000 claims 1
- 229940112534 lumigan Drugs 0.000 claims 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 229960004640 memantine Drugs 0.000 claims 1
- 229960004083 methazolamide Drugs 0.000 claims 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 239000004090 neuroprotective agent Substances 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 229960004605 timolol Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229960002368 travoprost Drugs 0.000 claims 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims 1
- 229960004317 unoprostone Drugs 0.000 claims 1
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33811701P | 2001-12-03 | 2001-12-03 | |
| US40050402P | 2002-08-02 | 2002-08-02 | |
| PCT/US2002/038040 WO2003047513A2 (en) | 2001-12-03 | 2002-11-27 | Method for treating ocular hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514378A JP2005514378A (ja) | 2005-05-19 |
| JP2005514378A5 true JP2005514378A5 (https=) | 2005-12-22 |
Family
ID=26991044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548774A Withdrawn JP2005514378A (ja) | 2001-12-03 | 2002-11-27 | 高眼圧症の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1461026A2 (https=) |
| JP (1) | JP2005514378A (https=) |
| AU (1) | AU2002346562A1 (https=) |
| CA (1) | CA2466757A1 (https=) |
| WO (1) | WO2003047513A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410591B1 (en) * | 2001-05-08 | 2002-06-25 | Allergan Sales, Inc. | 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| US7872045B2 (en) * | 2001-06-14 | 2011-01-18 | Allergan, Inc. | Combination therapy for glaucoma treatment |
| EP1461026A2 (en) * | 2001-12-03 | 2004-09-29 | Merck & Co., Inc. | Method for treating ocular hypertension |
| AU2003211574A1 (en) * | 2002-03-05 | 2003-09-16 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| AU2011202937B2 (en) * | 2002-05-14 | 2012-06-07 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
| US7053085B2 (en) | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
| US7256211B1 (en) | 2003-01-21 | 2007-08-14 | Ono Pharmaceutical Co., Ltd. | 8-azaprostaglandin derivatives and medical use thereof |
| US7235586B2 (en) * | 2003-09-09 | 2007-06-26 | Allergan, Inc. | Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| ATE550323T1 (de) | 2004-06-04 | 2012-04-15 | Allergan Inc | Piperidinyl-prostaglandinanaloga als den augeninnendruck senkende mittel |
| US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
| US8013159B2 (en) | 2005-05-19 | 2011-09-06 | Merck Canada Inc. | Quinoline derivatives as EP4 antagonists |
| WO2008058766A1 (en) | 2006-11-16 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| WO2011047048A1 (en) | 2009-10-14 | 2011-04-21 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
| WO2014015247A1 (en) * | 2012-07-19 | 2014-01-23 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| PT2989098T (pt) | 2013-03-15 | 2017-08-16 | Cayman Chemical Co Inc | Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4 |
| CA2903314C (en) | 2013-03-15 | 2023-02-14 | Cayman Chemical Company, Inc. | Methods of synthesizing a difluorolactam analog |
| US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
| KR20160048054A (ko) | 2013-07-19 | 2016-05-03 | 카이맨 케미칼 컴파니 인코포레이티드 | 골 성장의 촉진을 위한 방법, 시스템 및 조성물 |
| KR102456567B1 (ko) | 2013-08-09 | 2022-10-19 | 알데릭스, 인코포레이티드 | 인산염 수송을 억제하기 위한 화합물 및 방법 |
| WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1461026A2 (en) * | 2001-12-03 | 2004-09-29 | Merck & Co., Inc. | Method for treating ocular hypertension |
| EP1490055A1 (en) * | 2002-03-18 | 2004-12-29 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2002
- 2002-11-27 EP EP02784630A patent/EP1461026A2/en not_active Withdrawn
- 2002-11-27 JP JP2003548774A patent/JP2005514378A/ja not_active Withdrawn
- 2002-11-27 AU AU2002346562A patent/AU2002346562A1/en not_active Abandoned
- 2002-11-27 CA CA002466757A patent/CA2466757A1/en not_active Abandoned
- 2002-11-27 WO PCT/US2002/038040 patent/WO2003047513A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514378A5 (https=) | ||
| RU2005132930A (ru) | Аналоги простагландина в качестве антагонистов ep4 рецепторов | |
| JP2005514378A (ja) | 高眼圧症の治療方法 | |
| JP2011116768A (ja) | 眼圧降下剤としての８−アザプロスタグランジン類似体 | |
| JP2019142977A (ja) | 緑内障予防又は治療のための薬物療法 | |
| JP2010031041A (ja) | 降圧脂質（プロスタグランジン誘導体）およびチモロールの組成物ならびにその使用方法 | |
| AU5001199A (en) | Ophthalmic compositions for treating ocular hypertension | |
| CA2488001A1 (en) | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma | |
| JP2009137971A (ja) | 薬剤および薬剤キット | |
| RU2002114335A (ru) | Комбинированные агенты для лечения глаукомы | |
| JP2004503601A (ja) | 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法 | |
| ES2210018T3 (es) | Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma. | |
| TW201143773A (en) | Compositions & methods for lowering intraocular pressure | |
| JP2005538061A5 (https=) | ||
| US10363258B2 (en) | Treatment of migraines | |
| US20040254230A1 (en) | Method for treating ocular hypertension | |
| JP2014510022A (ja) | 眼精疲労の処置方法 | |
| JPWO2020081562A5 (https=) | ||
| JP2005533055A5 (https=) | ||
| TWI809021B (zh) | 含有ＦＰ促效藥及β阻斷藥的青光眼治療劑 | |
| JP2003292442A (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
| JP2006021998A (ja) | Ｅｐ２アゴニストを有効成分とする月経困難症治療剤 | |
| JP4677705B2 (ja) | 頭痛の予防および／または治療剤 | |
| HK40020724A (en) | Low-dose brimonidine combinations and uses thereof | |
| Bross | Case Study: Travoprost: A Potent PGF2α Analog |